Vaxart

NCT01335347

Safety Study of an Oral Vaccine to Prevent Avian Influenza

NCT01688297

Safety Study of an Oral Vaccine to Prevent Seasonal Influenza

NCT01698060

Immunogenicity of ND1.1 by Delivery Directly to the Ileum

NCT01761123

Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum

NCT02547792

Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy Adults

NCT02830932

Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)

NCT02868073

Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine

NCT03121339

Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults

NCT03125473

Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers

NCT03721549

Evaluation of Infectivity and Illness of Norwalk GI.1 Virus Lot 001-09NV in the Human Challenge Model

NCT03897309

Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines

NCT04563702

Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects

NCT04854746

Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine

NCT05213728

A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers

NCT06944717

A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old